Semaglutide Doses for Alcohol Use Disorder and Obesity
Compares 2 semaglutide doses with placebo in adults with alcohol use disorder and obesity.
Plain-language title generated from the registry record
Registry title: Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
Key facts
- Where
- New Haven, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 68 years old?
Source: NCT07772960, who can take part
Where in United States
- Yale Stress CenterNew Haven, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yale University
- Trial code
- NCT07772960
- Record updated
- 4 November 2026
- Original description
This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.Read full original descriptionShow less
Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.
Inclusion: Male and females ages 18-60 and BMI in 30-49.9 kg/m2; regular weekly alcohol use (at least 3X/week) prior to admission; must meet current DSM-V criteria for moderate to severe Alcohol Use Disorders (AUDs) using SCID-I for DSM-V; Good health as verified by screening and physical examination; Able to read English and complete study evaluation; Able to provide informed written and verbal consent.
Exclusion: Current use of any anti-obesity medications; Prior history of bariatric surgery or current intragastric balloon; Meet current criteria for moderate to severe substance use disorders from abuse of any another psychoactive substance, excluding nicotine; Current use of psychiatric medications, including benzodiazepine-based sedatives/anxiolytics and anticonvulsants, non SSRI antidepressants, oral prescription analgesics (other than non-steroidal anti-inflammatory drugs), acamprosate, naltrexone, antabuse, baclofen, varenicline; Endocrine or immune disorders, including diagnosis of diabetes (T2D or T1D) by American Diabetes Association (ADA) criteria or a history of HgbA1c >6.5% and on current medications for T2D treatment; Significant underlying medical conditions, including history of pancreatitis, acute kidney injury, medullary thyroid cancer, or MEN syndrome, as well as other cerebral, renal, thyroid or cardiac pathology that would preclude study participation; Current use of opiates; Psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania); Current participation in structured meal replacement or weight loss program; Weight loss of >=10% over the preceding 6 months; Women who are pregnant, nursing or refuse use of reliable form of birth control.